Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

被引：0
|
作者：
Janne B Kjersem
Tone Ikdahl
Tormod Guren
Eva Skovlund
Halfdan Sorbye
Julian Hamfjord
Per Pfeiffer
Bengt Glimelius
Christian Kersten
Hiroko Solvang
Kjell M Tveit
Elin H Kure
机构：
[1] Institute for Cancer Research,Department of Genetics
[2] Oslo University Hospital,Department of Oncology
[3] Oslo University Hospital,School of Pharmacy
[4] University of Oslo and the Norwegian Institute of Public Health,Department of Oncology
[5] Haukeland University Hospital,Department of Oncology
[6] Odense University Hospital,Department of Radiology, Oncology and Radiation Science
[7] Uppsala University,Department of Oncology and Pathology
[8] Karolinska Institutet,Center for Cancer Treatment
[9] Southern Hospital Trust,undefined
来源：
BMC Cancer | / 12卷
关键词：
Colorectal cancer; LCS6; MiRNA polymorphism; Cetuximab; Oxaliplatin; 5-fluorouracil;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 37 条
  • [31] Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
    Soeda, Hiroshi
    Shimodaira, Hideki
    Watanabe, Mika
    Suzuki, Takao
    Gamoh, Makio
    Mori, Takahiro
    Komine, Keigo
    Iwama, Noriyuki
    Kato, Shunsuke
    Ishioka, Chikashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 670 - 677
  • [32] A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
    Z Saridaki
    N Androulakis
    N Vardakis
    L Vamvakas
    E Kabouraki
    K Kalbakis
    D Hatzidaki
    A Voutsina
    D Mavroudis
    V Georgoulias
    J Souglakos
    British Journal of Cancer, 2012, 107 : 1932 - 1937
  • [33] A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
    Saridaki, Z.
    Androulakis, N.
    Vardakis, N.
    Vamvakas, L.
    Kabouraki, E.
    Kalbakis, K.
    Hatzidaki, D.
    Voutsina, A.
    Mavroudis, D.
    Georgoulias, V.
    Souglakos, J.
    BRITISH JOURNAL OF CANCER, 2012, 107 (12) : 1932 - 1937
  • [34] HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/ Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
    Garziera, Marica
    Virdone, Saverio
    De Mattia, Elena
    Scarabel, Lucia
    Cecchin, Erika
    Polesel, Jerry
    D'Andrea, Mario
    Pella, Nicoletta
    Buonadonna, Angela
    Favaretto, Adolfo
    Toffoli, Giuseppe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [35] Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)
    Moriwaki, Toshikazu
    Bando, Hideaki
    Takashima, Atsuo
    Yamazaki, Kentaro
    Esaki, Taito
    Yamashita, Keishi
    Fukunaga, Mutsumi
    Miyake, Yasuhiro
    Katsumata, Kenji
    Kato, Satoshi
    Satoh, Taroh
    Ozeki, Mitsuharu
    Baba, Eishi
    Yoshida, Shigemasa
    Boku, Narikazu
    Hyodo, Ichinosuke
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2842 - 2848
  • [36] Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)
    Toshikazu Moriwaki
    Hideaki Bando
    Atsuo Takashima
    Kentaro Yamazaki
    Taito Esaki
    Keishi Yamashita
    Mutsumi Fukunaga
    Yasuhiro Miyake
    Kenji Katsumata
    Satoshi Kato
    Taroh Satoh
    Mitsuharu Ozeki
    Eishi Baba
    Shigemasa Yoshida
    Narikazu Boku
    Ichinosuke Hyodo
    Medical Oncology, 2012, 29 : 2842 - 2848
  • [37] Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
    Stahler, A.
    Heinemann, V.
    Giessen-Jung, C.
    Crispin, A.
    Schalhorn, A.
    Stintzing, S.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Quietzsch, D.
    Held, S.
    von Einem, J. C.
    Holch, J.
    Neumann, J.
    Kirchner, T.
    Jung, A.
    Modest, D. P.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (03) : 739 - 746
1234